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The current epidemic of obesity and cardiometabolic diseases in developing countries is described as being driven
by socioeconomic inequalities. These populations have a greater vulnerability to cardiometabolic diseases due to
the discrepancy between the maternal undernutrition and its consequence, low-birth weight progeny, and the
subsequent modern lifestyles which are associated with socioeconomic and environmental changes that modify
dietary habits, discourage physical activity and encourage sedentary behaviors. Maternal undernutrition can generate
epigenetic modifications, with potential long-term consequences. Throughout life, people are faced with the challenge
of adapting to changes in their environment, such as excessive intake of high energy density foods and sedentary
behavior. However, a mismatch between conditions experienced during fetal programming and current environmental
conditions will make adaptation difficult for them, and will increase their susceptibility to obesity and cardiovascular
diseases. It is important to conduct research in the Latin American context, in order to define the best strategies to
prevent the epidemic of cardiometabolic diseases in the region.
Keywords: Obesity, Cardiovascular diseases, Maternal undernutrition, Low-birth weight, Socio-economic
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Overweight and obesity are defined as a body mass
index (BMI) of 25–29.9 and greater than or equal to
30 kg/m2, respectively. Worryingly, prevalence is in-
creasing at an alarming rate throughout the world and it
has been projected that in 2030, there will be 2.16 billion
overweight and 1.12 billion obese people in the world
[1]. Developing countries have seen a proportionally lar-
ger increase in the number of overweight and obese in-
dividuals. For instance, some years ago it was reported
that a third of the population in Latin America were
overweight or obese [2,3], whereas current data suggests
that it has increased to around half of the adults [4].
This trend is thought to be driven by the rapid and un-
equal socio-economic development that Latin America is
experiencing. Significant nutritional changes, including* Correspondence: jplopezj@gmail.com
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article, unless otherwise stated.increases in high energy density foods consumption, with
a parallel decreases in physical activity levels, due to the
mechanization of both daily work and leisure-time activ-
ities [5-8], are being observed. Moreover, the migration
from rural to urban areas could be also contributing to
these lifestyle changes [9].
Despite the increased prevalence of obesity and over-
weight, maternal undernutrition and its consequence,
low-birth weight progeny, remains an important public
health concern in many developing regions, such as
Latin America [10]. This condition may be also a conse-
quence of the unequal socio-economic development ob-
served in the region, since both maternal undernutrition
and placental dysfunction induced by preeclampsia or
infections, can lead to intrauterine growth restriction
(IUGR) [11]. Indeed, socio-economic inequality is a de-
terminant of poor access of pregnant women belonging
to a low socio-economical stratum to an adequate diet
and to an appropriate prenatal care [10,12], in turn risk
factors for the mentioned placental disorders, and hence,
for IUGR.Central. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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trition during the fetal development and early in the
extra uterine life is associated with increased risk of car-
diometabolic disease in adulthood [13,14]. Therefore,
the main goal of this review is to explain, from our point
of view, how the socio-economic inequality mediated by
a mismatch between maternal undernutrition and expos-
ure to westernized lifestyles in later life is contributing
to the current increasing prevalence in obesity and car-
diometabolic diseases in the Latin American population.
Moreover, we will review the association between these
trends and epigenetic adaptations, insulin resistance and
low-degree inflammation.
The Cardiometabolic disease situation in Latin
America
There have been large shifts in the morbi-mortality trends
in Latin America in recent decades, moving from a domin-
ance of transmissible to a dominance of non-transmissible
chronic diseases, including cardiovascular and metabolic
diseases [2,5,9,15]. For example, while national, regional
and global trends in fasting plasma glucose and diabetes
prevalence since 1980 [16], show that glycemia levels and
type 2 diabetes mellitus (DM2) are an increasing hazard
worldwide (Table 1); higher prevalences are reported in
some regions, including Oceania and Latin America. In
fact, the estimated increase in the number of people with
DM2 in Latin America will be over 150% in just three de-
cades, from 15 million in 1995 to 39 million in 2025 [17].
Results of small studies confirm these exceptionally high
prevalences of DM2, such as values as high as 43.3% in
Puerto Rico [18]. The lowest prevalence has been reported
in Peru (5% in Lima) [19].
In relation to obesity, a systematic analysis reported by
the Global Burden of Metabolic Risk Factors of Chronic
Diseases Collaborating Group demonstrated that between
1980 and 2008, the mean BMI increased worldwide byTable 1 Global trends in fasting plasma glucose and
diabetes prevalence (1980 vs. 2008)
Variables 1980 2008
Global FPG (mmol/L)*
Men 5.29** 5.50 (5.37–5.63)
Women 5.15** 5.42 (5.29–5.54)
DM2 prevalence (%)*
Men 8.3 (6.5–10.4) 9.8 (8.6–11.2)
Women 7.5 (5.8–9.6) 9.2 (8.0–10.5)
People with DM2 (million)*
Men 77 (60–97) 173 (151–197)
Women 76 (58–97) 173 (151–197)
*Age-standardized values. **Estimated values from the published data [16].
Data is presented as mean (95% uncertainty interval). FPG: fasting plasma
glucose. DM2: diabetes mellitus type 2.0.4 kg/m2 per decade for men and 0.5 kg/m2 per decade
for women. In Latin America the largest rise in BMI oc-
curred in females, in which rises of 1.3 kg/m2 per decade
were observed [20]. In global terms it is clear that the
poorest countries in Latin America, such as Haiti,
Honduras and Bolivia, have the lowest rates of obesity.
However, similar rates of increase are observed in
these countries as in the region as a whole [1,3], being
higher in women, and disproportionately affecting
groups from lower socio-economic strata who are liv-
ing in urban areas [3].
Moreover, the metabolic syndrome (MetS) has been al-
ways considered as a major public health concern. It was
first described predominantly in developed countries such
as the United States, where a prevalence of 24% in the
adult population was reported [21]. Nonetheless, various
further studies in Latin American countries [19,22-28],
have demonstrated that currently these countries have a
similar or even higher prevalence of MetS in adults than
developed countries (Table 2).
Less data is available about the prevalence of MetS
and its components in children and adolescents in Latin
America. A small study of children and adolescents of
Bolivia reported a high frequency of MetS (36% of the
sample) [29], and in another recent study, in Chilean ad-
olescents 37.5% presented with MetS [30]. Therefore,
while malnourishment remains a large problem in a sub-
stantial proportion of poor Latin American children,
obesity is emerging in alarming rates, principally in the
most developed sectors in these countries [8]. For ex-
ample, we recently reported a lower prevalence of un-
dernutrition (4.4%) in school age Colombian children
than of overweight (12.9%) and obesity (9.8%) [31].
The non-communicable chronic disease situation in
Latin America is one that is of concern not only in terms
of prevalence, but also due to its low rates of awareness,
treatment and control. The Prospective Urban and RuralTable 2 Prevalence of metabolic syndrome in Latin
American countries






Chile 2003 1833 ≥17 ATP-III 32.0
IDF 37.0
Mexico 2006 6021 20 to 69 ATP-III 36.8
IDF 49.8
Venezuela 2001 3108 ≥20 ATP-III 31.2
Ecuador 2004 352 ≥65 IDF 40.0
Peru 2006 1878 20 to 80 AHA/NHLBI 18.8
Brazil 2001 1655 25 to 64 ATP-III 32.9
Colombia 2007 1001 ≥18 ATP-III 45.6
IDF 50.4
Extracted values from published data [19,22-28]. MS: metabolic syndrome.
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countries (Argentina, Brazil, Colombia and Chile) are cur-
rently participating, recently reported worrisome global
and regional rates of awareness, treatment and control of
hypertension [32], as well as a very low use of the proven
effective secondary preventive drugs in those patients with
a previous history of coronary heart disease or stroke [33].
Moreover, among these individuals with self-reported cor-
onary heart disease or stroke, the prevalence of a healthy
lifestyle was also very low (Table 3) [34]. The Latin American
situation is of concern when compared to high-income
countries. The above situations are other examples of the
poor access to adequate health care in our population, so
as it is prenatal care for mothers.
In this context, the social and financial costs of obesity
and cardiometabolic diseases are also increasing at ex-
cessively high rates. Certainly, premature mortality and
temporary and permanent disability generated as com-
plications of non-communicable chronic diseases repre-
sent an enormous burden for patients and their families,
as well as for the health system and society in general
[35]. For example, obesity has been shown to account
for up to 16% of the global burden of disease, expressed
as a percentage of disability-adjusted life-years. More-
over, there has been described that around of 10% of
total health care costs in the developed world are attrib-
utable to obesity [36]. This is especially worrisome in
emerging economies, such as Latin Americans.
Several strategies have been implemented to reduce
the burden of cardiovascular diseases (CVD) in LatinTable 3 Global and Latin American rates of awareness,
treatment and control of cardiovascular diseases – PURE
study







Antiplatelet drugs 25.3 29.0
β-blockers 17.4 28.8
ACE / ARB 19.5 37.9
Statins 14.6 15.0
Healthy lifestyle
Smoking cessation 53.4 67.2
Physical activity 35.1 41.5*
Healthy diets 39.0 43.2*
Extracted values from published data [32-34]. *Data for the global lower-middle-income
countries, where the Latin Americans are included. ACE: angiotensin-converting-enzyme
inhibitors. ARB: angiotensin-receptor blockers.America. For instance, recently the Latin American
consensus on hypertension in patients with DM2 and
MetS was published [37] to serve as a guide for physi-
cians taking care of patients with these diseases and
comorbidities. In addition, the Latin American Society
of Hypertension (LASH) defined ‘the initiative 20/20’
as an institutional goal, which aims to improve the
awareness, treatment and control of hypertension in
20% by the year 2020 [38]. Unfortunately, all these im-
portant actions are only mitigating the problem, but do
not address the causes of non-communicable chronic dis-
eases. We therefore believe that several public health pol-
icies should be adopted which are aimed at reducing
social inequality in our region, since it is underlies the link
between early life conditions, including intrauterine, and
the regional epidemic of cardiometabolic diseases in later
life, as we are going to review below.
Maternal undernutrition, epigenetics and
cardiometabolic diseases
Inter-population differences in the prevalence of cardio-
vascular and metabolic diseases and its associated risk
factors may reflect differences in the quality of life status
between them, which could be influenced by several en-
vironmental factors, such as physical activity and dietary
patterns. However, genetic background might also play a
key role, since the genome is programmed to express ap-
propriate sets of genes, in particular tissues, at specific
time points during the individual’s life. Even more im-
portant however, may be the genetic-environment inter-
action in the pathogenesis of cardiometabolic diseases,
which can induce epigenetic modifications [10,13,14].
By definition, epigenetics refers to modifications in
gene expressions that are controlled by changes in DNA
methylation and/or chromatin structure [39], and might
play an important role in the pathogenesis of various en-
tities, including cancer and cardiometabolic diseases.
Epigenetic events are heritable, although occasionally re-
versible, depending on endogenous, but specially ex-
ogenous (environmental) signals, creating a memory of
cell identity [40], and maintaining genomic functions
after differentiation, propagation of essential features of
chromosomal architecture, and dosage compensation
[41]. Therefore, epigenetic modifications could lead to ir-
reversible processes of differentiation and organogenesis
or to labile and potentially reversible changes in homeo-
static processes [14]. Moreover, environmental signals
such as food depletion and stress have been present
throughout evolution, and organisms have had to sense
and adapt to them, to ensure their survival. These epigen-
etic modifications occur not only in humans, but have also
been implicated in the control of various parameters of
gene expression, genetic recombination, DNA repair, and
DNA mutagenesis in bacteria, plants, and animals [42].
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histone modifications, and microRNAs [43], and can
help to explain how individuals with identical or similar
DNA, when exposed to different environmental signals,
express diverse phenotypes and differ in their suscepti-
bility to certain pathologies. Thus, chromatin structure
can be linked to environmental factors such as diet, nu-
trients, drugs or the socio-economic environment in sev-
eral ways [40,44]. From this perspective, we propose that
the very rapid change from undernutrition to overnutri-
tion in Latin American and the Caribbean countries
[3-5], a consequence of the socio-economic transition
process, may be producing an epigenetic maladaptation
in these populations.
There is an interesting discrepancy between developed
and developing countries, and the causal direction of the
relationship between socio-economic conditions and
obesity and CVD is complex. In developing countries, at
the start of the epidemiologic and nutrition transition, a
higher socio-economic level was associated with a more
unhealthy diet and higher levels of obesity, while over
time a gradual shift and reversal of this relationship hasFigure 1 Epigenetic modifications and environmental influences on tbeen observed. Currently, higher socio-economic status
is associated with knowledge of good nutrition and life-
style choices and an inverse relation between socio-
economic levels and obesity is being observed, as found
in developed countries. Meanwhile, later in the transi-
tion process, poorer people in developing countries have
adopted increasingly unhealthy lifestyles and changes in
their nutritional habits [5,7,8], trends currently occurring
in the Latin American population. Thus, in these popu-
lations, westernized habits of high energy intake and low
energy expenditure during adulthood contrast substan-
tially with the epigenetic fetal programming based on
maternal conditions of undernutrition, thereby mediat-
ing an increased susceptibility to high incidence of car-
diovascular and metabolic diseases (Figure 1).
During early human and animal development, exogen-
ous or environmental signals and changes could induce
epigenetic modifications, which have potential long-term
consequences [40,45]. In some populations, poor mater-
nal nutrition has been associated with increased risk of
DM2 over several generations [14,46]. Moreover, placental
insufficiency, inadequate maternal nutrition, metaboliche pathogenesis of cardiometabolic diseases.
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epigenetic programming during early development, which
could partially explain lifelong imbalance between energy
intake and energy expenditure in individuals with MetS,
obesity, DM2 and CVD [14,46-51].
Indeed, human epidemiological studies and appropri-
ately designed dietary interventions in animal models have
provided considerable evidence to suggest that maternal
nutritional imbalance and metabolic disturbances, during
critical time windows of development, may have a persist-
ent effect on the health of offspring and may even be
transmitted to the next generation [14,47,52-57]. As a
consequence, the hypotheses of “fetal programming” and
its new denomination: “developmental origins of health
and disease” were proposed, describing the early nutrition
during gestation and lactation as a common risk factor for
chronic diseases, such as obesity, CVD, diabetes, hyper-
tension, asthma, cancer and even schizophrenia [58-66].
Furthermore, cohort studies after famine also suggest
that several adulthood diseases are related to the duration
and timing of nutritional deficit during the gestational
period. As epigenetic plasticity changes continuously from
conception to death, effects will vary according to whether
the exposure occurs during preconception, pregnancy, lac-
tation, neonatal life, early life, pre-/post-menopause, or
puberty [53]. Furthermore, several other processes, such
as chromosomal instability, telomere shortening, meta-
bolic cycles, mitochondrial deteriorations, and oscillatory,
circadian or seasonal rhythms of systemic hormone levels
(hypothalamic–pituitary–adrenal axis), could also affect
epigenetic plasticity [50,52,58,59,67-70]. In principle, the
earlier the epigenetic changes occur, the greater their
physiologic/metabolic impact such that epigenetic modifi-
cations that occur during embryogenesis and early fetal
development would be transmitted over consecutive
mitotic divisions, affecting many more cells than those
occurring during postnatal development [55]. Data from
the Dutch Winter Hunger cohort revealed that those de-
scendants of mothers who were severely undernourished
during the early stage of pregnancy were more likely to
develop CVD than those born to mothers whose preg-
nancies were more advanced at the time of nutritional
deficit [71-73].
Various conditions and nutritional restrictions during
pregnancy have been linked with a number of different
metabolic outcomes on their offspring in humans and
animals. Low maternal protein consumption or poor vita-
min B and methionine status are associated with behav-
ioral and cardiovascular abnormalities, and sex-specific
changes in hepatic gene expression in rat fetuses and
changes in imprinted gene expression in the rat embryo-
fetal axis [40,74-76]. Katari et al. [77] highlighted the asso-
ciation between in-vitro conception and changes in DNA
methylation, in turn affecting the long-term pattern ofexpression of genes involved in chronic metabolic disor-
ders such as obesity and DM2. Pinney and Simmons [78]
studied epigenetic events at the promoter of the gene en-
coding Pdx-1, a critical transcription factor (TF) for beta-
cell function and development, the expression of which is
reduced in intra uterine growth restriction (IUGR), a situ-
ation that has been associated with the development of
diabetes in adulthood [15,40,78]. As mentioned above,
IUGR can be a consequence of maternal undernutrition
and can predispose to the development of DM2 in the
new born when exposed to different, energy-rich diet in
later life [10,13]. Raychaudhuri et al. [79] focused on the
sequence of epigenetic mechanisms responsible for the
weak expression of Glut-4 in the skeletal muscle of indi-
viduals with IUGR. They found that perinatal nutrient re-
striction resulting in IUGR leads to histone modifications
in skeletal muscle that directly decrease Glut-4 gene ex-
pression. This effectively creates a metabolic knockdown
of an important regulator of peripheral glucose transport
and insulin resistance, thereby contributing to the adult
DM2 phenotype [79].
In addition, it has been demonstrated that IUGR may
be related to such vascular abnormalities as stiffness of
the abdominal aorta [80], reduced arterial compliance
[81], narrower retinal arteriolar caliber [82], and endo-
thelial dysfunction [83], factors which also contribute to
the development of CVD later in life. Maternal protein
restriction during pregnancy may also result in a de-
clined skeletal muscle mass of the progeny [84]. In a re-
cent study it was shown in IUGR pigs that their total
number of muscle fibers was lower when compared with
normal body weight animals [85]. Furthermore, there
was altered the expression of 37 proteins involved in the
proliferation and differentiation of muscle fibers, energy
supply, protein metabolism, nutrient transport, intracel-
lular environment, and tissue integrity. We recently
demonstrated in a population of Colombian children
from low socio economical strata, an association be-
tween low muscle strength and increased levels of adi-
pocytes, C-reactive protein (CRP), HOMA index and
metabolic risk factors [31]. Moreover, in a sub-analysis
of the ORIGIN study [86] we demonstrated that low
handgrip strength is an important factor associated to
an increased risk of cardiovascular mortality in predia-
betic and diabetic patients.
Furthermore, even pre-implantation development in
mammals has recently been shown to be sensitive to en-
vironmental conditions [87]. Results of both in-vivo and
in-vitro experiments, have demonstrated that environ-
mental factors can modify blastocyst potential and lead
to long-term changes in fetal and postnatal health and
physiology. For example, elevated concentrations of plasma
homocysteine have been found in pre-implantation em-
bryos, which have low mtDNA copy number and
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ment inhabited by breeding females before conception
and early in pregnancy has striking effects on the oo-
cytes developing in the ovarian follicle and embryos in
the early stages of development in the reproductive
tract. Environmental conditions at these stages may
also alter behavior, cardiovascular function and repro-
ductive function throughout postnatal life [40,89-92].
Consequently, fetal and neonatal periods are critical
for the development and growth of the systems involved
in cardiometabolic pathways. In rats, detrimental effects
on growth during fetal and early postnatal life can nega-
tively affect both the number [93] and secretor function
of pancreatic beta-cells [94]. Some years ago, Hales and
colleagues demonstrated that men with a low-birth weight
were six times more likely to have DM2 at 64 years of age
than men with a high-birth weight [95]. Moreover, it has
been demonstrated that children who had a low-birth
weight but had increased rates of growth at 7 years old
had a further increased risk of developing DM2 later in
life [96]. Hence, it is interesting to propose that the in-
creased rates of cardiovascular and metabolic diseases,
currently observed in Latin America could be the result of
the discrepancy between the restricted nutritional envir-
onment during fetal development and early life, and the
environment of nutritional abundance during adulthood.
This discrepancy causes a mismatch between the fetal
programming of the organism’s metabolic pathways and
their adult circumstances, characterized by the imposition
of new obesogenic lifestyles [5,10,13,15].
Moreover, recent studies have found significant differ-
ences in DNA methylation profiles in aged monozygotic
twins with a history of non-shared environments, suggest-
ing that environmentally mediated epigenetic changes also
occur throughout life [97,98]. For example, important
CVD risk factors such as hypercholesterolemia, obesity,
hyperhomocysteinemia, and hyperglycemia could stimu-
late the inflammatory process and its long-term effects via
epigenetic reprogramming, promoting differentiation of
monocytes/macrophages into more pro-atherogenic phe-
notypes [99-102].
Abdominal obesity, insulin resistance and low
degree inflammation
Overweight and obesity have been well described as
important risk factors for CVD [12,103,104] and DM2
[3,5,103], and to be associated with an increased preva-
lence of other cardiovascular risk factors [103]. Recently,
in Colombian adults with severe coronary disease, we re-
ported that abdominal obesity is associated with leptin/
adiponectin imbalance, decreased endothelium-dependent
relaxation and an enhanced response to angiotensin-II.
These changes occurred independently of other cardiovas-
cular risk factors and therefore suggest that these vascularalterations, promoted by abdominal obesity, could be the
initial event that leads to insulin resistance, low degree in-
flammation, atherosclerosis and CVD [104].
Moreover, the INTERHEART [105] and the INTER-
STROKE [106] studies, which included Latin American
countries (Argentina, Brazil, Chile, Colombia, Ecuador,
Peru), demonstrated that abdominal obesity, evaluated
by waist-to-hip ratio, was a more sensitive risk factor
than BMI in subjects that presented a first event of myo-
cardial infarction and stroke. Furthermore, abdominal
obesity is considered as the key factor in the onset of
MetS, a cluster of hypertension, dysglycemia, low HDL
cholesterol, increased triglycerides, and abdominal obes-
ity. MetS is also related to an increased risk of DM2 and
CVD [107], an important consideration given that ab-
dominal obesity is highly prevalent in Latin America.
A recent report of the International Day for Evaluation
of Abdominal Obesity (IDEA) study [108], showed that
the mean waist circumference in a Latin American pri-
mary care population was 96.4 cm and 89.7 cm for men
and women, respectively. This study also confirmed the
association between increased abdominal obesity and
the presence of DM2 and CVD in our population. How-
ever, the cutoff point to diagnose abdominal obesity in the
Latin American population remains controversial. A study
conducted in Colombian subjects with no previous CVD
history, reported that the criteria for waist circumference
proposed by the International Diabetes Federation (90 cm:
men, 80 cm: women) is more useful for identifying sub-
jects with MetS than that proposed by the Adult Treat-
ment Panel III (102 cm: men, 88 cm: women) [22]. In
addition, several studies [109,110] carried out in develop-
ing countries have reported lower waist circumference
cutoff points for cardiovascular risk than those reported in
developed countries. In healthy young Colombian men, a
waist circumference of 88 cm identified subjects with car-
diovascular risk with a sensitivity of 83.7% and a specificity
of 84.8% [111]. In Ecuador [112], it was demonstrated that
a waist circumference of 90 cm in men is the best cutoff
point associated with the presence of at least two of the
other MetS criteria according to the Adult Treatment
Panel III.
Recently, it has become evident that the visceral adipos-
ity content is crucial in determining risk of developing
DM2 and CVD [113]. Waist circumference was reported
to be an easy to implement measure for evaluating the
content of visceral fat, which is the main source of pro-
inflammatory cytokines [113-116]. Moreover, some studies
have observed that the concentration of pro-inflammatory
cytokines is higher in the Latin American population than
that reported in the population of developed countries,
suggesting a higher sensitivity of this population to de-
velop systemic low-degree inflammation in response to
abdominal obesity [117,118]. These cytokines are elevated
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posed that the systemic inflammation produced by the
adipose tissue participates in all stages of the development
of cardiometabolic diseases, such as endothelial dysfunc-
tion [120], atheroma formation, rupture of plaque, and
acute thrombotic complications [121,122]. C-reactive pro-
tein (CRP), produced by the liver in response to the stimu-
lus of TNF-alpha and interleukin-6, is increased in subjects
with multiple acute coronary events and is a strong inde-
pendent predictor of new acute coronary events [123]. We
have demonstrated in the Andean region that CRP is an in-
dependent risk factor for essential hypertension [124] and
preeclampsia [125,126]. Moreover, the concentration of
CRP is increased in dyslipidemic subjects with MetS [127]
and in overweight children [128].
All these studies confirm that Latin Americans have
an increased risk of developing cardiometabolic diseases
at lower levels of abdominal obesity. We propose that
this observation could be mediated by epigenetic modifi-
cations acquired during fetal development, which could
affect visceral adipose tissue and predispose to an in-
flammatory imbalance. Recently, we found evidence of
regional differences in adiponectin levels in subjects with
MetS, especially between developed vs. developing coun-
tries [129]. However, we were not able to ascertain
whether the lower adiponectin values observed in sub-
jects with MetS from developing countries were related to
genetic and or epigenetic factors. Therefore, additional
studies are required to further test this hypothesis.
Inflammation has been described as an adaptation to
the disruption of homeostasis at a cellular and tissue
level and affects many important processes, such as host
defense, tissue remodeling and repair, and the regulation
of metabolism. All of processes related to the inflamma-
tory response require coordinated control in some con-
ditions, and independently in others [130,131]. This is
accomplished with the participation of several mecha-
nisms that operate at different levels, including alter-
ations in the composition of immune cells in tissues,
changes in cell responsiveness to inflammatory stimuli,
regulation of signaling pathways and epigenetic control
of gene expression [66].
For example, signal-specific mechanisms operating at
the molecular level can activate the key transcription
factor (TF) nuclear factor-kB (NFkBTF), which is prob-
ably the most important TF and mediator of inflamma-
tion, since it controls the expression of more than 400
genes [132-134]. In addition, NFkBTF is involved in in-
creasing inflammatory disease and malignancy by indu-
cing transcription of soluble mediators that amplify
inflammation, angiogenesis and neoplastic cell prolifera-
tion, and promoting progression to more aggressive dis-
ease states [135]. Moreover, infectious agents and over
nutrition, specifically via metabolic and endoplasmicreticulum (ER) stress, are some of the numerous stim-
uli that can activate to NFkBTF family. Indeed, a con-
siderable constitutive activity of NFkBTF and its
associated processes has been observed in many can-
cer cells, inflammatory disorders, obesity and insulin
resistance [132,133,136-143].
Obesity is characterized by a chronic exposure to high
energy intake and positive energy balance, and ER is the
organelle responsible for responding to these challenges.
ER acts as a key nutrition sensor of cellular metabolic
parameters, such as hyperglycemia, fatty acid overload,
hypoglycemia, and oxidative stress, and participates in
almost all anabolic and catabolic processes. Therefore,
an eventual failure of the ER’s adaptive capacity would
affect many different inflammatory and stress signaling
pathways at the crossroad of inflammation, cancer and
metabolic disease [138,139,144].
Besides the molecular and cellular levels, there are
some gene-specific mechanisms operating at the level of
individual genes and gene subsets. Several TF and extra-
genic noncoding RNAs participate in the induction of
inflammatory transcriptional responses by acting on in-
flammatory enhancers [145-148]. Hence, a well-ordered
expression of cytokine genes is a crucial component of
an immune response and is decisive for homeostasis.
Various factors, including the type of cytokine, as well as
the cell type, dose range and the kinetics of its expres-
sion are extremely important to generate an appropriate
response to metabolic stress or an infectious condition
[149-151]. Recently, several efforts have been made to
modulate epigenetic factors, such as via hyper/hypome-
thylation of key inflammatory genes by external and
dietary factors, aiming to cure or protect against inflam-
matory disease [53,152-156].
Different cell types constitutively express primary-
response TF in their cytoplasm and these are activated
by signal-dependent post-translational modifications,
which involve their nuclear translocation, such as NFkB,
IRF, and CREB. These transcription factors are mainly
responsible for the primary phase of gene induction and
integrate signals from diverse signaling pathways that
can amplify or terminate signal-dependent TF activation.
Other classes of TF, such as C/EBPd, require de novo
synthesis following inflammatory stimulation. Most are
constitutively nuclear and regulate secondary waves of
gene expression. Other class of constitutively nuclear TF
is expressed in a cell type-specific and differentiation-
dependent manner, such as Runx, PU.1, IRF8, AP1, and
C/EBP [146,157]. They establish cell type-specific pat-
terns of gene expression and are involved in chromatin
remodeling during cell differentiation and organization
of high-order chromatin structure and chromosomal do-
mains. The TF of these categories do not act independently,
but function coordinately to control the inflammatory
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expression profiling of inflammatory genes and in silico
motif scanning of promoters of these genes they can de-
fine gene clusters that are coordinately regulated and
the TF that are likely to control their expression
[130,132,134,141,149,157-160]. As TF bind very poorly,
or not at all, to nucleosomal DNA, their activation is there-
fore coordinated to the recruitment of ATP-dependent
chromatin-remodeling factors, histone-enzyme complexes,
methylases, demethylases, acetylases, and deacetylases,
amongst other substances. Parallel post-translational mod-
ifications such as phosphorylation, acetylation, methyla-
tion, ribosylation, sumoylation, and ubiquitination of
histone and non-histone TF and cofactor complexes, per-
mit formation of dynamic enhanceosome complexes
which establish a distinct chromatin structure. Ultimately,
all of these epigenetic reactions and modifications are the
decisive step in which both environmental and differentia-
tive inputs determine the correct or incorrect expression
of each inflammatory gene [66,132,158,160-162].Conclusion
Socioeconomic inequalities are emerging as an import-
ant determinant of the current worldwide epidemic of
obesity and CVD. While the relationship between socio-
economic conditions and obesity and CVD is inconsist-
ent in developed countries, in developing countries there
appears to be a strong association between the two. As a
possible explanation, it is suggested that in developing
countries maternal disadvantage leads to a low-birth
weight as a consequence of poor health behaviors, ex-
posure to harmful environmental factors, poorer access
to medical care, and less worse underlying maternal
health. Later in life, due to the socioeconomic transition,
these children have been exposed to a greater access to
energy-dense diets, and an increased risk of developing
obesity and CVD. We therefore argue that a key solution
to address this public health concern is the implementa-
tion of public policies which aim to reduce socioeconomic
inequalities. Despite having achieved some important
goals, it is noteworthy that we are fighting a huge
enemy - the increasing epidemic of CVD driven by our
social inequalities. Therefore, the great challenge is to
continue to develop and implement research in our
population which aims to find regional-specific solu-
tions to resolve a worldwide problem.Abbreviations
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